3rd September 2024, Quezon City, Philippines Delex Pharma International Inc. has launched an impressive array of 11 new pharmaceutical products in the first half of 2024, setting the stage for significant growth across multiple therapeutic areas. This launch reflects Delex Pharma’s commitment to addressing critical healthcare needs in the Philippines, particularly in the fields of critical care, oncology, anesthesia, and medical devices.
Delex Pharma is the 3rd largest in the hospital channel (Ref.: iQVIA MAT Dec 2020) and an ISO 9001:2015-certified Filipino-owned pharma and medical device company with top-notch global partners. With a focus on penetrating ethical and medical device businesses, Delex Pharma offers a diverse portfolio in critical care, anesthesia, anti-infectives, oncology, and medical devices.
Delex Pharma aims to become a market leader in hypertensive emergency drugs, particularly those used in emergency rooms, operating theaters, and intensive care units. The introduction of
Betalex (Labetalol Hydrochloride) is a strategic move in this direction. Betalex is the only drug actively promoted in this segment for obstetric cases as well as for neurological indications, positioning it to capture a significant share of the market currently dominated by Nicardipine, with an estimated value of PHP 800 million.
In the Philippines, hypertensive disorders like preeclampsia and eclampsia remain a leading cause of maternal mortality, accounting for up to 30% of maternal deaths according to the Department of Health’s 2017 Philippine Health Statistics. With intravenous labetalol being the recommended first-line therapy for preeclampsia due to its effectiveness, rapid onset, and safety profile, Betalex is poised to address a critical need in the market.
Betalex’s launch is complemented by the introduction of Glisenit (Nitroglycerin), which together are expected to capture 50% of the Nicardipine market in the next two years, especially given the growing availability of these products in major hospitals across the country. Nicardipine has been previously utilized on OB-GYN and neuro cases due to the unavailability of labetalol and nitroglycerin in the market.
Recognizing the rapid growth in the oncology sector, where revenue in the Philippines is projected to reach USD 274.60 million by 2024, Delex Pharma has strategically expanded its portfolio with five new oncology products: Docelex (Docetaxel), Fluoracilex (Fluorouracil), Fosfalex (Ifosfamide), Paclitex (Paclitaxel), and D-Xobin (Doxorubicin HCI).
These products are not only driving demand but are also readily available through Delex Pharmacy ensuring convenient access for cancer patients nationwide. These high-quality drugs are sourced from Kemex Laboratory, Argentina, further enhancing their appeal to the market. Kemex is a leading pharmaceutical company specializing in the production of high-quality oncological medicines. They are committed to continuous national and international expansion, with their growth driven by their core values of quality, efficiency, safety, and accessibility.
View https://www.facebook.com/DelexOnlinePharmacy
In response to the increasing demand for pain management solutions, particularly among cancer patients, Delex Pharma has launched Fentalex (Fentanyl Patch), which has quickly become the best-selling drug in Delex Pharmacy. Additionally, the company has introduced Predex (Dexmedetomidine) and Delexofol (Propofol), further solidifying its presence in the anesthesia market.
These anesthesia products are being promoted in synergy with innovative medical devices such as Smiths/ICU Medical CADD Solis and Verathon GlideScope. Through Memorandum of Agreement (MOA) contract bundles with hospitals, Delex Pharma ensures these essential drugs and devices are widely available and accessible in major healthcare facilities.
Delex Pharma continues to innovate with the launch of Axaline (Sodium Chloride), the first premixed hypertonic saline 3% solution available in the market for fluid therapy in neuropatients. This product addresses a critical need in neurological care and further expands Delex Pharma’s footprint in neurosurgery.
The introduction of these 11 new products is expected to contribute an additional 20% to Delex Pharmas total revenue in 2024. The company is poised for further expansion with a second tranche of new product launches planned for August to December 2024, which will continue to drive growth and strengthen its market position.
BNCM is an Asset Management Company that secures its assets by investing in companies with strong growth potentials, robust revenues, significant profits, proven track records, and promising business models with highly experienced management teams that will exceptionally qualify for quotation, listing on the OTC, NASDAQ markets within the next 2 to 3 years. The growth of these companies will directly provide more employment opportunities to the communities, improve the country’s economy, and bring greater social change to humanity.
For more information, visit: https://www.bncm.net/
DELEX is a Delaware-registered company, and a holding company of DLX Holdings, Inc. (DLX). DLX is a Philippine-based parent company that holds a 60% controlling interest in Delex Pharma International, Inc. an ISO 9001-2015 Certified company which also holds a controlling interest in JMN Brother’s Pharma Limited, Inc. DLX and its subsidiaries are involved in the development and distribution of pharmaceutical and healthcare products in the Philippines.
For more information, visit: https://delexhealth.com
